Academic Journal
Q1Cancer
About Cancer
Cancer is a scholarly journal published by John Wiley and Sons Inc. SCImago 2025 places it in Q1 with an SJR of 2.427 and an H-index of 359.
Its listed coverage is 1948-2026 and its research categories include Cancer Research (Q1); Oncology (Q1). The 2025 dataset reports 588 documents and 7160 citations across the latest three-year reporting window.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Lymphoma Diagnosis and Treatment, Breast Cancer Treatment Studies, Global Cancer Incidence and Screening, Sarcoma Diagnosis and Treatment, Head and Neck Cancer Studies, Lung Cancer Treatments and Mutations.
Recent Research Articles
Latest publications matched automatically by ISSN.
Elevated risk of ischemic stroke after invasive cancer diagnosis: A nationwide population‐based study
Carmit Libruder, David Tanne, Barbara G. Silverman, Binyamin Binyaminy et al.
2026-09-15 · DOI: 10.1002/cncr.70536Issue Information
2026-09-15 · DOI: 10.1002/cncr.70605Long‐term outcomes and patterns of failure in patients with thymic malignancies treated with surgery and radiation therapy
Oded Icht, Inbar Nardi‐Agmon, Paaladinesh Thavendiranathan, Shaf Keshavjee et al.
2026-09-15 · DOI: 10.1002/cncr.70595HERMES trial supports shortened SBRT schedule without added toxicity for patients with prostate cancer
Leah Lawrence
2026-09-01 · DOI: 10.1002/cncr.70538FDA grants accelerated approval to BCL‐2 inhibitor sonrotoclax for mantle cell lymphoma
Leah Lawrence
2026-09-01 · DOI: 10.1002/cncr.70537FDA approves test for molecular residual disease monitoring in patients with solid tumors
Leah Lawrence
2026-09-01 · DOI: 10.1002/cncr.70539GPRC5D‐targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies
Darren Pan, Anupama Kumar, Jodi J. Lipof, Alfred Chung et al.
2026-09-01 · DOI: 10.1002/cncr.70597Interpreting a borderline signal in colorectal cancer screening among sexual and gender minority adults
Christos Zavos
2026-09-01 · DOI: 10.1002/cncr.70598Adjuvant CDK4/6 inhibitors in early‐stage breast cancer: Clinical evidence and considerations for risk stratification and treatment selection
Austin D. Williams, Anna Weiss
2026-09-01 · DOI: 10.1002/cncr.70587Reply to “Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?”
Moath Albliwi, Daniel P. Nurse, Emily C. Zabor, John Hanna et al.
2026-09-01 · DOI: 10.1002/cncr.70593Racial differences in multiple myeloma survival: Associations with stem cell transplantation, insurance, and Medicaid expansion
F. Lennie Wong, Scott R. Goldsmith, Kimlin Ashing, Amrita Krishnan et al.
2026-09-01 · DOI: 10.1002/cncr.70596The burden of male breast cancer (MBC) in the GBD Central, Eastern, and Western Europe Regions from 1990 to 2023: Results from the Global Burden of Disease Study 2023
Roberto Passera, Elisa Fabbro, Giulia Zamagni
2026-09-01 · DOI: 10.1002/cncr.70585Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?
Niveditha Suresh Babu, K. S. Sridevi Sangeetha
2026-09-01 · DOI: 10.1002/cncr.70592Cancer statistics for Asian American, Native Hawaiian, and Pacific Islander people, 2026
Nikita Sandeep Wagle, Angela N. Giaquinto, Mandi Yu, Hyuna Sung et al.
2026-09-01 · DOI: 10.1002/cncr.70584Vimseltinib for patients with tenosynovial giant cell tumor: A multicenter, open‐label, phase 2 trial
Silvia Stacchiotti, Jean‐Yves Blay, Piotr Rutkowski, Hans Gelderblom et al.
2026-09-01 · DOI: 10.1002/cncr.70564Gynecologic cancers in low‐ and middle‐income countries: Bridging the survival gap
Dewi Setiawati, Wachyudi Muchsin, Alfi Sophan
2026-09-01 · DOI: 10.1002/cncr.70518Beyond risk factors: A capacity framework for cancer survivorship research
Keith M. Bellizzi
2026-09-01 · DOI: 10.1002/cncr.70582Issue Information
2026-09-01 · DOI: 10.1002/cncr.70579Reviews
Community Reviews
Version History
September 8, 2026 at 12:00 am
September 8, 2026